Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (45)

2024

  1. Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutations

    European Heart Journal

  2. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials

    eClinicalMedicine, Vol. 76

  3. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

  4. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review

    Frontiers in Cardiovascular Medicine, Vol. 11

  5. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 776-784

  6. Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 851-858

2023

  1. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome

    GeroScience, Vol. 45, Núm. 2, pp. 1231-1236

  2. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  3. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  4. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  5. Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

    European heart journal

  6. Personalizing anti-inflammatory therapy in heart failure: A new way

    European Journal of Heart Failure

  7. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 704-720

2022

  1. CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia

    Scientific Reports, Vol. 12, Núm. 1

  2. COLCHICINE ANTI-INFLAMMATORY THERAPY FOR NON-INTENSIVE CARE UNIT HOSPITALIZED COVID-19 PATIENTS: RESULTS FROM A PILOT OPEN-LABEL, RANDOMIZED CONTROLLED CLINICAL TRIAL

    Journal of Physiology and Pharmacology, Vol. 73, Núm. 3

  3. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

  4. Environmental factors like air pollution: not to be forgotten in the 2021 ESC guidelines on heart failure. Response

    Revista Espanola de Cardiologia

  5. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial

    Frontiers in Pharmacology, Vol. 13

  6. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

  7. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2170-2180